Overview

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Status:
Recruiting

Trial end date:
2022-06-15

Target enrollment:

Participant gender:

Summary

This study evaluates the combination of lenvatinib with denosumab in bone-predominant metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas. All patients will receive this combination of treatments.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Leon Berard

Treatments:

Denosumab
Lenvatinib